Simplex Trading
VRDN icon

Simplex Trading’s Viridian Therapeutics VRDN Stock Holding History

Simplex Trading’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
700
-31,900
-98% -$514K ﹤0.01% 7486
2026
Q1 		$638K Buy
+32,600
New +$968K ﹤0.01% 2990
2025
Q3 		– Sell
-100
Closed -$1K – 10179
2025
Q2 		$1K Sell
100
-12,600
-99% -$171K ﹤0.01% 8461
2025
Q1 		$171K Sell
12,700
-40,600
-76% -$692K ﹤0.01% 4512
2024
Q4 		$1.02M Sell
53,300
-26,200
-33% -$570K ﹤0.01% 2823
2024
Q3 		$1.81M Buy
79,500
+76,600
+2,641% +$1.25M ﹤0.01% 2363
2024
Q2 		$37K Buy
2,900
+1,200
+71% +$16.6K ﹤0.01% 6375
2024
Q1 		$29K Sell
1,700
-1,200
-41% -$23.3K ﹤0.01% 6787
2023
Q4 		$63K Buy
+2,900
New +$45.8K ﹤0.01% 5869
2023
Q3 		– Sell
-61,300
Closed -$1.46M – 9947
2023
Q2 		$1.46M Buy
61,300
+59,300
+2,965% +$1.52M ﹤0.01% 2232
2023
Q1 		$50K Sell
2,000
-23,200
-92% -$744K ﹤0.01% 5936
2022
Q4 		$736K Buy
25,200
+23,600
+1,475% +$544K ﹤0.01% 2778
2022
Q3 		$32K Buy
+1,600
New +$28.8K ﹤0.01% 7002

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simplex Trading's VRDN Position: Q2 2026 in Review

Simplex Trading opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 270 shares worth $4.96K. The stake represents ﹤0.01% of the portfolio and ranks #8181 among its holdings. This is a return to the name: Simplex Trading previously reported a position in VRDN as recently as Q3 2025.

Simplex Trading first reported a position in VRDN in Q2 2022 and has held it in 11 quarters since. The position peaked at $556K in Q2 2023. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Simplex Trading held 270 shares of Viridian Therapeutics worth $4.96K as of Q2 2026.
  • Viridian Therapeutics was a new Simplex Trading position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8181 holding.
  • Simplex Trading first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Simplex Trading's Viridian Therapeutics position peaked at $556K in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.